BioInvent International
LUND, SWEDEN / ACCESSWIRE / October 28, 2021 / BioInvent International (STO:BINV)
"The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio. The integration of functions, on top of world leading science, makes it possible for us to develop novel treatments for patients suffering from serious diseases. The solid balance sheet and strong, loyal shareholders support us in achieving our goals," said Martin Welschof, BioInvent CEO.
Events in the quarter
• (R) BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.
• Emma Meurling joined Bioinvent as Human Resource (HR) Director.
Events after the period
• BioInvent and Transgene announced that preclinical data for BT-001, a novel oncolytic virus delivering an anti-CTLA-4 antibody for the treatment of solid tumors, will be presented at SITC in November 2021.
• New data on the lead drug candidate BI-1206 Phase 1/2a study in non-Hodgkin's lymphoma (NHL) to be presented at the ASH (American Society of Hematology) conference December 11-14.
• New production agreement with CRUK to produce additional batch of anti-HER3 antibody.
• Prof. Eggermont new member of the BioInvent Scientific Advisory Board.
Financial information
Third quarter 2021
• Net sales SEK 3.0 (16.3) million.
• Loss after tax SEK -62.6 (-32.9) million.
• Loss after tax per share before and after dilution SEK -1.07 (-1.00).
• Cash flow from operating activities -57.5 (-31.4) million.
January - September 2021
• Net sales SEK 14.5 (48.6) million.
• Loss after tax SEK -199.7 (-104.9) million.
• Loss after tax per share before and after dilution SEK -3.79 (-4.00).
• Cash flow from operating activities SEK -170.1 (-91.8) million.
• Liquid funds and long-term investments as of September 30, 2021: SEK 1,445.3 (642.1) million.
The complete report is attached as pdf and is available on the company's website www.bioinvent.com/investors/#financialreports.
(R)= Regulatory event
Contacts
Cecilia Hofvander
Senior Director Investor Relations
Tel: +46 46 286 85 50
Email. cecilia.hofvander@bioinvent.com
About Us
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow us on Twitter: @BioInvent.
Attachments
SOURCE: BioInvent International
View source version on accesswire.com:
https://www.accesswire.com/670065/BioInvent-International-AB-Interim-Report-January--September-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Masar Destination Achieves LEED for Communities Gold Certification23.1.2026 21:35:00 CET | Press release
Affirming its Commitment to Sustainability MAKKAH, SAUDI ARABIA / ACCESS Newswire / January 23, 2026 / Masar: a landmark urban development in the heart of Makkah, owned, developed, and operated by Umm Al Qura for Development & Construction Company, has been awarded LEED Gold certification under the LEED for Communities rating system, one of the highest international certifications in sustainability and the built environment. This achievement recognizes Masar's adoption of an integrated approach that places people and the environment at the heart of its design and planning processes. This accomplishment reflects the company's commitment to developing sustainable urban communities in line with global best practices. By balancing quality of life, resource efficiency, and environmental protection, it paves the way for long-term positive impact and a more sustainable future. Commenting on the achievement, Mr. Yasser Abuateek, Chief Executive Officer of Umm Al Qura for Development & Construc
Sir Ivan Releases "Love Is The Piece"23.1.2026 20:45:00 CET | Press release
The Peace Anthem of the 21st Century MIAMI, FLORIDA / ACCESS Newswire / January 23, 2026 / Electronic Dance Music (EDM) recording artist, Sir Ivan, has co-written and recorded a peace song that will stand the test of time. Inspired by 20th-century anti-war rock legends such as John Lennon and Bob Dylan, Sir Ivan's new single, "Love Is The Piece," is a bold reminder to all generations that love remains the only path to peace and is found only in our hearts. Stream/Download On All Platforms "As the son of an Auschwitz survivor (see UnstoppableSiggi.com), my life has been deeply affected by the tragedy of having over 50 family members murdered during the Holocaust, simply because they were Jewish. My father's miraculous survival and my subsequent birth had a purpose. And that purpose was for me to one day write and sing a peace song that would help stop violence, bloodshed, and war between people. That song is ‘Love Is The Piece,'" declared Sir Ivan. While global conflicts and civil unres
From NASA to Your Boardroom: Freelancer Opens 85-Million-Mind Innovation Engine to All Enterprises23.1.2026 14:00:00 CET | Press release
The platform that slashed NASA's R&D costs and compressed three-day computations into one hour is now available to any organisation Previous challenge winner's spacecraft solution is bound for space What do you do when your toughest technical problem stumps every expert in your building? If you're NASA, you throw it open to 85 million minds across 140 countries. Starting today, any company can do the same. SAN FRANCISCO, CA / ACCESS Newswire / January 23, 2026 / Freelancer (ASX:FLN) announced the global launch of its Moonshot Innovation Program, opening the breakthrough platform that has delivered over 20,000 solutions to NASA, NIH, and the CDC to enterprises worldwide. The same system that helped NASA save 80-99% on R&D costs, compressed Bureau of Reclamation river modelling from 72 hours to 60 minutes, and generated 54 genome therapy breakthroughs for NIH is now available to any organization with a problem that traditional consulting can't crack. The results speak louder than any pit
Datavault AI Inc. Completes Acquisition of API Media23.1.2026 12:00:00 CET | Press release
Technology Provider API Media extends Datavault AI and the patented ADIO Technology to the Live Outdoor Event Market PHILADELPHIA, PA / ACCESS Newswire / January 23, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI" or the "Company"), a leader in data monetization, credentialing, digital engagement and real‑world asset tokenization technologies, today announced that it has closed its previously announced acquisition of API Media Innovation Inc ("API"), a provider of media infrastructure and event technology solutions. API, headquartered in New Jersey, has a decades-long tradition of providing innovative audio and visual technologies to the world of media, sports, and entertainment. API's clients include some of the most prestigious and sought-after sports venues and events, made possible through a dedicated and customer-first culture cultivated over decades. "We are pleased to complete this acquisition, which marks a decisive next step in our strategy to scale Datavault AI's propr
Aviwell Closes €11 Million Series A Investment Round to Scale AI‑Driven Microbiota Platform for Sustainable Animal Nutrition23.1.2026 06:01:00 CET | Press release
TOULOUSE, FRANCE AND BOSTON, MA / ACCESS Newswire / January 23, 2026 / Aviwell SAS, a deep‑tech animal nutrition company headquartered in Toulouse, today announced the successful completion of a €11 million Series A investment round, welcoming three new investors: Blue Revolution Fund (BRF), Blast.Club, and SWEN Capital Partners. The financing will support Aviwell's next phase of growth as the company scales its AI‑driven microbiome discovery and development platform and advances native, nature‑based biological solutions for global agri‑food markets, initially focused on poultry and aquaculture. Built on decades of research pioneered by Aviwell's co‑Founder, Prof. Remy BURCELIN, into how naturally occurring bacterial ecologies administered early in life can have a durable impact on animal growth, health, and resilience, Aviwell has developed Aneto™, an AI‑powered microbiome discovery platform. Aneto™ identifies specific molecular mechanisms - modes of action - that enable the selection
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom